A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.

The invention provides a breath test for assessing a metabolic phenotypeand/or assessing a disease state.

Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed.

The invention describes a method for functional characteristics of proteins for classification of patients to be associated to a specific disease performed in a computing device by applying biophysical parameters as an input to a marker linear combination, wherein the marker linear combination comprises a predefined combination of at least two biophysical parameters, using the marker linear combination to determine the input parameters relating to one or more of said predetermined diseases, and outputting a result according to the marker linear combination, wherein the marker linear combination comprises at least one of the biophysical parameters: a binding constant of a spin probe, a polarity surrounding a spin probe, an order parameter of a spin probe, a rotation correlation time of a spin probe, a spectral component from free spin probe molecules, a spectral component from spin probe on lipid-fraction of serum, or a geometry factor.

The present disclosure provides methods for generating an in vitro model of cholestatic liver disease and uses of the same. In some embodiments, the methods involve an in vitro culture system for producing hepatocyte-like cells from pluripotent stem cells.

The present invention provides a novel antibody targeting TLR9.

RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.

Described herein are methods and compositions for treating a liver disease. Aspects of the invention relate to administering to a subject an agent that inhibits WISP1. Another aspect of the invention relates to administering to a subject a HSC that expresses and agent that inhibits WISP1.

The present invention is related to the in vitro use of lyso-Gb1 as a draggable target in the development of a drug, and to antagonist of lyso-Gb1 for use in the treatment and/or prevention of a disease, wherein the disease is Gaucher disease or Parkinson's disease